Health Care & Life Sciences » Biotechnology | Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals Inc. | Ownership

Companies that own Alexion Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
T. Rowe Price Associates, Inc.
22,050,828
9.9%
1,217,537
0.37%
06/30/2018
Fidelity Management & Research Co.
18,213,174
8.17%
97,793
0.23%
06/30/2018
The Vanguard Group, Inc.
15,288,422
6.86%
266,401
0.06%
06/30/2018
BlackRock Fund Advisors
11,580,856
5.2%
-718,961
0.07%
06/30/2018
SSgA Funds Management, Inc.
9,811,542
4.4%
706,426
0.09%
06/30/2018
Baker Bros. Advisors LP
8,555,894
3.84%
0
6.8%
06/30/2018
Columbia Management Investment Advisers LLC
6,245,697
2.8%
36,711
0.44%
06/30/2018
Jennison Associates LLC
6,028,122
2.71%
-1,459,471
0.63%
06/30/2018
ClearBridge Investments LLC
4,486,767
2%
442,473
0.47%
06/30/2018
Norges Bank Investment Management
3,600,667
1.62%
1,535,617
0.06%
12/31/2017

About Alexion Pharmaceuticals

View Profile
Address
121 Seaport Boulevard
Boston Massachusetts 02210
United States
Employees -
Website http://www.alexion.com
Updated 07/08/2019
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.